HQY
NEUTRAL
$77.96
Live
HealthEquity, Inc. · NASDAQ
Target $112.88
(+44.8%)
$72.76
52W Range
$116.65
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 11, 2026
Market cap
$6.66B
P/E
31.69
ROE
10.2%
Profit margin
16.4%
Debt/Equity
0.48
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
HQY presents a stark divergence between strong fundamental earnings performance and bearish market sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 4/9 and excellent liquidity (Current Ratio 3.27). While the current price of $77.96 trades at a premium to its intrinsic value ($72.57) and Graham Number ($37.04), the Forward P/E of 14.60 suggests significant expected earnings expansion. However, the bullish fundamental outlook is heavily countered by a 0/100 technical trend and consistent insider selling.
Key Strengths
Explosive YoY earnings growth of 92.40%
Strong liquidity position with a current ratio of 3.27
Impressive gross margins of 69.52%
Consistent track record of earnings beats over 25 quarters
Conservative leverage with a Debt/Equity ratio of 0.48
Key Risks
Strongly bearish technical trend (0/100)
Net insider selling activity across multiple executives
Current price exceeds growth-based intrinsic value ($72.57)
Modest revenue growth (7.30%) relative to earnings growth
Lack of dividend yield providing no floor for price corrections
AI Fair Value Estimate
Based on comprehensive analysis
$82.0
+5.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
56
Moderate
50
80
90
60
0
AI Verdict
Fundamental Growth vs Sentiment Drag
Key drivers: Forward P/E compression, Consistent earnings surprise history, Bearish technicals and insider selling
Confidence
80%
Value
50/100
Current P/E 31.69 vs Forward P/E 14.60
Positives
- Attractive Forward P/E of 14.60
Watchpoints
- Price is significantly above Graham Number ($37.04)
- Trading above intrinsic value estimate
Future
80/100
Earnings growth is outstripping revenue growth, suggesting margin expansion
Positives
- Massive YoY earnings growth (92.4%)
- Strong analyst target price ($112.88)
Watchpoints
- Low single-digit revenue growth
Past
90/100
Consistent ability to beat analyst estimates
Positives
- Exceptional 25-quarter earnings track record
- Average surprise of 11.4% over last 4 quarters
Watchpoints
No urgent risks highlighted.
Health
60/100
Strong balance sheet but mediocre Piotroski score
Positives
- Low Debt/Equity (0.48)
- High Quick Ratio (2.82)
Watchpoints
- Piotroski F-Score of 4/9 is only 'Stable'
Dividend
0/100
Payout ratio 0.00%
Positives
No standout positives identified.
Watchpoints
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$77.96
Analyst Target
$112.88
Upside/Downside
+44.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HQY and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HQY
HealthEquity, Inc.
Primary
|
+11.9% | +34.2% | -2.5% | -13.9% | -0.8% | -7.9% |
|
RGEN
Repligen Corporation
Peer
|
-39.7% | -30.0% | -7.4% | -11.9% | -5.7% | +1.3% |
|
ACLX
Arcellx, Inc.
Peer
|
+580.9% | +279.9% | +59.8% | +50.1% | +63.7% | +0.1% |
|
GRFS
Grifols, S.A.
Peer
|
-51.1% | +11.6% | +28.0% | -11.9% | +2.2% | -0.4% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-42.2% | -50.0% | -58.5% | -29.4% | -10.7% | -2.7% |
HQY
HealthEquity, Inc.
Primary
5Y
+11.9%
3Y
+34.2%
1Y
-2.5%
6M
-13.9%
1M
-0.8%
1W
-7.9%
RGE
Repligen Corporation
Peer
5Y
-39.7%
3Y
-30.0%
1Y
-7.4%
6M
-11.9%
1M
-5.7%
1W
+1.3%
ACL
Arcellx, Inc.
Peer
5Y
+580.9%
3Y
+279.9%
1Y
+59.8%
6M
+50.1%
1M
+63.7%
1W
+0.1%
GRF
Grifols, S.A.
Peer
5Y
-51.1%
3Y
+11.6%
1Y
+28.0%
6M
-11.9%
1M
+2.2%
1W
-0.4%
MOH
Molina Healthcare, Inc.
Peer
5Y
-42.2%
3Y
-50.0%
1Y
-58.5%
6M
-29.4%
1M
-10.7%
1W
-2.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
31.69
Forward P/E
14.6
PEG Ratio
N/A
P/B Ratio
3.15
P/S Ratio
5.07
EV/Revenue
5.53
EV/EBITDA
15.08
Market Cap
$6.66B
Profitability
Profit margins and return metrics
Profit Margin
16.38%
Operating Margin
21.64%
Gross Margin
69.52%
ROE
10.19%
ROA
5.99%
Growth
Revenue and earnings growth rates
Revenue Growth
+7.3%
Earnings Growth
+92.4%
Q/Q Revenue Growth
+7.3%
Q/Q Earnings Growth
+88.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.48
Low debt
Current Ratio
3.27
Strong
Quick Ratio
2.82
Excellent
Cash/Share
$3.77
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Revenue
$0.3B
Gross Margin
68.2%
Op. Margin
21.6%
Net Margin
14.9%
Total Assets
$3.4B
Liabilities
$1.3B
Equity
$2.1B
Debt/Equity
0.60x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
91%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-06-02
$N/A
2026-03-17
$0.95
+5.8% surprise
2025-12-03
$1.01
+10.7% surprise
2025-09-02
$1.08
+17.7% surprise
Healthcare Sector Comparison
Comparing HQY against 226 companies in the Healthcare sector
(19 bullish, 76 neutral, 131 bearish)
P/E Ratio
31.69
This Stock
vs
45.29
Sector Avg
-30.0%
(Discount)
Return on Equity (ROE)
10.19%
This Stock
vs
-40.43%
Sector Avg
-125.2%
(Below Avg)
Profit Margin
16.38%
This Stock
vs
-18.65%
Sector Avg
-187.9%
(Weaker)
Debt to Equity
0.48
This Stock
vs
4.61
Sector Avg
-89.7%
(Less Debt)
Revenue Growth
7.3%
This Stock
vs
97.21%
Sector Avg
-92.5%
(Slower)
Current Ratio
3.27
This Stock
vs
3.51
Sector Avg
-6.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HQY
HealthEquity, Inc.
|
NEUTRAL | $6.66B | 31.69 | 10.2% | 16.4% | $77.96 | |
|
RGEN
Repligen Corporation
|
NEUTRAL | $6.64B | 137.0 | 2.4% | 6.6% | $117.82 | Compare |
|
ACLX
Arcellx, Inc.
|
BEARISH | $6.69B | - | -53.4% | -% | $114.39 | Compare |
|
GRFS
Grifols, S.A.
|
NEUTRAL | $6.74B | 12.83 | 6.2% | 5.3% | $8.21 | Compare |
|
MOH
Molina Healthcare, Inc.
|
NEUTRAL | $7.09B | 15.25 | 11.0% | 1.1% | $136.03 | Compare |
HQY
HealthEquity, Inc.
NEUTRAL
Mkt Cap
$6.7B
P/E
31.7
ROE
10.2%
Price
$77.96
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-25 | ROSNER ELIMELECH | Chief Technology Officer | Stock Award | 60,607 | - |
| 2026-03-25 | FIORE MICHAEL HENRY | Officer | Stock Award | 17,582 | - |
| 2026-03-25 | GATHRIGHT MICHAEL | Officer | Stock Award | 15,157 | - |
| 2026-03-25 | NEELEMAN STEPHEN | Officer and Director | Stock Award | 39,775 | - |
| 2026-03-25 | LUCANIA JAMES M | Chief Financial Officer | Stock Award | 27,283 | - |
| 2026-03-25 | LADD DELANO W IV | General Counsel | Stock Award | 35,608 | - |
| 2026-03-25 | CUTLER SCOTT RAYMOND | Chief Executive Officer | Stock Award | 72,754 | - |
| 2026-02-02 | NATARAJAN RAJESH | Director | Stock Award | 976 | - |
| 2026-02-02 | PARKER STUART B | Director | Stock Award | 1,263 | - |
| 2025-12-19 | NEELEMAN STEPHEN | Officer and Director | Gift | 140,000 | - |
| 2025-12-19 | LADD DELANO W IV | General Counsel | Sale | 1,500 | $142,080 |
| 2025-12-18 | ROSNER ELIMELECH | Chief Technology Officer | Sale | 10,959 | $1,046,090 |
| 2025-12-17 | NEELEMAN STEPHEN | Officer and Director | Gift | 500 | - |
| 2025-12-12 | WELLBORN GAYLE FURGURSON | Director | Sale | 4,339 | $425,331 |
| 2025-12-12 | WELLBORN GAYLE FURGURSON | Director | Option Exercise | 4,339 | $218,729 |
ROSNER ELIMELECH
Chief Technology Officer
2026-03-25
60,607 shares
FIORE MICHAEL HENRY
Officer
2026-03-25
17,582 shares
GATHRIGHT MICHAEL
Officer
2026-03-25
15,157 shares
NEELEMAN STEPHEN
Officer and Director
2026-03-25
39,775 shares
LUCANIA JAMES M
Chief Financial Officer
2026-03-25
27,283 shares
LADD DELANO W IV
General Counsel
2026-03-25
35,608 shares
CUTLER SCOTT RAYMOND
Chief Executive Officer
2026-03-25
72,754 shares
NATARAJAN RAJESH
Director
2026-02-02
976 shares
PARKER STUART B
Director
2026-02-02
1,263 shares
NEELEMAN STEPHEN
Officer and Director
2025-12-19
140,000 shares
LADD DELANO W IV
General Counsel
2025-12-19
1,500 shares
·
$142,080
ROSNER ELIMELECH
Chief Technology Officer
2025-12-18
10,959 shares
·
$1,046,090
NEELEMAN STEPHEN
Officer and Director
2025-12-17
500 shares
WELLBORN GAYLE FURGURSON
Director
2025-12-12
4,339 shares
·
$425,331
WELLBORN GAYLE FURGURSON
Director
2025-12-12
4,339 shares
·
$218,729
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
16 analysts
BMO Capital
2026-04-09
Market Perform
Outperform
Deutsche Bank
2026-03-19
Buy
Buy
Barrington Research
2026-03-18
Outperform
Outperform
JP Morgan
2026-03-18
Overweight
Overweight
RBC Capital
2026-03-18
Outperform
Outperform
Barclays
2026-02-18
Overweight
Overweight
BTIG
2026-02-17
Buy
Buy
Goldman Sachs
2026-01-09
Neutral
Sell
Keybanc
2026-01-08
Overweight
Overweight
Barclays
2025-12-09
Overweight
Past News Coverage
Recent headlines mentioning HQY from our newsroom.
Newest → oldest
No matching news yet.